Finally, the significantly improved survival (77 ± 11 days), exhibited by the remaining HER2high+ tumor-bearing mice (n = 3) treated with CART-HER2 cells, indicated the specific antitumor activity of CART-HER2 cells. The gene discussed is ERBB2; the disease is neoplasm.